Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | August 18, 2026 | August 20, 2026 |
| Genesis Unicorn Capital Corp.GENQ · Entity 129525 | Chief Executive Officer | February 14, 2022 | March 04, 2022 |
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,600 |
Reported balance
After 2026-08-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 2,000 · Balance 31,600 F1: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
Genesis Unicorn Capital Corp.
Report date February 14, 2022 · Filed March 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-02-14 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the Registration Statement on Form S-1 (File No. 333-257623) under the heading "Description of Securities-Founder Shares and Placement Shares, the Class B Common Stock, par value $0.0001 per share of Genesis Unicorn Capital Corp., a Delaware corporation (the "Issuer") will automatically convert into shares of Class A Common Stock, par value $0.0001 of the Issuer at the time of the Issuer's initial business combination, on a one-for-one basis, subject to adjustment for share splits, share dividends, reorganizations, recapitalizations and similar transactions, and certain antidilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Registration Statement on Form S-1 (File No. 333-257623) under the heading "Description of Securities-Founder Shares and Placement Shares, the Class B Common Stock, par value $0.0001 per share of Genesis Unicorn Capital Corp., a Delaware corporation (the "Issuer") will automatically convert into shares of Class A Common Stock, par value $0.0001 of the Issuer at the time of the Issuer's initial business combination, on a one-for-one basis, subject to adjustment for share splits, share dividends, reorganizations, recapitalizations and similar transactions, and certain antidilution rights and have no expiration date.
Tonix Pharmaceuticals Holding Corp.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.28 · Expires 2036-05-12 | Direct | 22,700 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 22,700 · Balance 22,700 F1: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 21:25 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,000 | $86.96 | $173,920.00 |
DisclosureSEC source: 0001242615-26-000002 · wk-form4_1787261143.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,600 F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:47 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 22,700 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001999371-26-010753 · olukotun-form4_051426.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 22,700 shares Expires 2036-05-12 F1 · price: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 827 | $68.48 | $56,632.96 |
DisclosureSEC source: 0001242615-25-000006 · wk-form4_1766530882.xml · nonDerivative · entry 3 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,600 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.38 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 6,083 | $68.04 | $413,887.32 |
DisclosureSEC source: 0001242615-25-000006 · wk-form4_1766530882.xml · nonDerivative · entry 2 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,427 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.62 to $68.30, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,090 | $66.70 | $206,103.00 |
DisclosureSEC source: 0001242615-25-000006 · wk-form4_1766530882.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,510 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.40, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:39 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001242615-25-000004 · wk-form4_1766101187.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,600 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:49 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $20.18 | $0.00 |
DisclosureSEC source: 0001999371-25-006242 · olukotun-form4.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-13 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. Read SEC document |
| January 23, 2025 Filed Jan 28, 2025 00:22 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 959 | $21.00 | $20,139.00 |
DisclosureSEC source: 0001628280-25-002716 · wk-form4_1738023770.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,781 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 22:12 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,850 | $20.00 | $57,000.00 |
DisclosureSEC source: 0001628280-24-052592 · wk-form4_1735596735.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,740 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 23:05 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 16,733 | $22.99 | $384,691.67 |
DisclosureSEC source: 0001628280-24-052273 · wk-form4_1734735909.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,590 F1 · shares: Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary date. Read SEC document |
| June 10, 2024 Filed Feb 28, 2025 22:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, par value $0.001 | 0.812 | $1.91 | $1.55 |
DisclosureSEC source: 0001839882-25-012471 · olukotun-form4_022825.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock. Read SEC document |
| May 23, 2024 Filed May 24, 2024 21:07 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 104,621 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001999371-24-006622 · olukotun-form4.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,621 Underlying: Common Stock · 104,621 shares Expires 2034-05-23 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 20:54 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 14,987 | $25.41 | $380,819.67 |
DisclosureSEC source: 0001628280-23-041966 · wk-form4_1703019238.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,854 F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| May 08, 2023 Filed May 10, 2023 21:11 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001839882-23-012502 · ownership.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-05-08 F2 · shares: Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023. F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders. F2 · derivative.underlying_shares: Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 23:04 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 11,350 | $32.65 | $370,577.50 |
DisclosureSEC source: 0001209191-23-016446 · doc4.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,867 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.36 to $32.88, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:17 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock · Derivative | 4,593 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-23-003071 · doc4.xml · derivative · entry 2 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593 Underlying: Common Stock · 4,593 shares Expires 2033-01-10 F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:17 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003071 · doc4.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,217 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:40 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 2,131,500 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001387131-22-006015 · ownership.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,131,500 Underlying: Common Stock · 2,131,500 shares Expires 2032-05-09 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| January 07, 2022 Filed Jan 8, 2022 01:11 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002593 · doc4.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,350 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:33 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 244 | $66.25 | $16,165.00 |
DisclosureSEC source: 0001209191-22-001328 · doc4.xml · nonDerivative · entry 3 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,950 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:33 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,916 | $65.04 | $124,616.64 |
DisclosureSEC source: 0001209191-22-001328 · doc4.xml · nonDerivative · entry 2 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,194 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.74 to $65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4 Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:33 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,890 | $64.26 | $121,451.40 |
DisclosureSEC source: 0001209191-22-001328 · doc4.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to $64.70, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:25 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,750 | $63.76 | $175,340.00 |
DisclosureSEC source: 0001209191-21-055966 · doc4.xml · nonDerivative · entry 2 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 21:25 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,250 | $63.76 | $143,460.00 |
DisclosureSEC source: 0001209191-21-055966 · doc4.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,750 F1 · kind: Open market sale pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:44 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 270,882 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001387131-21-005546 · ownership.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,882 Underlying: Common Stock · 270,882 shares Expires 2031-05-10 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001548 · doc4.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| August 13, 2020 Filed Aug 17, 2020 13:04 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, par value $0.001 | 5,350 | $0.94 | $5,029.00 |
DisclosureSEC source: 0001387131-20-007593 · olukotun-form4_081320.xml · nonDerivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,350 Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:30 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001387131-20-004489 · ownership.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-05-04 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| May 06, 2019 Filed May 8, 2019 11:21 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 30,000 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001387131-19-003412 · ownership.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-06 F1 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 20:08 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001615774-18-009357 · s112616_form4.xml · derivative · entry 1 OLUKOTUN ADEOYE Y · CIK 0001242615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-09-05 F1 · derivative.exercise_date: The option was granted on September 5, 2018 pursuant to the Issuer's 2018 Equity Incentive Plan and vests on the date of the Issuer's 2019 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.